![](https://investorshub.advfn.com/uicon/494668.png?cb=1566808978)
Wednesday, August 31, 2016 7:50:09 PM
"The fear is that the FDA will take a dim view of the whole CAR-T class, slowing down the progress of each program and forcing companies to delay their expected filings, as Juno already has."
If Oncosec can prove their hypothesis of turning non-responders into responders and make it to market with a viable solution to treating cancer with no adverse side affects ahead of other companies we will be in great shape.
What Punit needs to do is seize the opportunity when it arises. If we get the results we are expecting by years end, he really needs to get the word out on Oncosec and PR the crap out of this. We need articles printed in Forbes, Newsweek, Time magazine. Publicity! Inovio has gotten PR and airtime on tv (MADMONEY). We need some of that to get people interested here.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM